Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: Pembrolizumab (K)|DRUG: Placebo (P)|DRUG: Paclitaxel (X)|DRUG: Doxorubicin (A)|DRUG: Epirubicin (E)|DRUG: Cyclophosphamide (C)|DRUG: Endocrine therapy|RADIATION: Radiation therapy|PROCEDURE: Surgery
Sponsor: Merck Sharp & Dohme LLC